September 4, 2015 6:03 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Clovis Oncology (NASDAQ: CLVS) today announced that rociletinib, thecompany's oral targeted covalent (irreversible) mutant-selective inhibitorof epidermal growth factor receptor (EGFR) in development for the treatmentof EGFR-mutated, T790M positive non-small cell lung cancer (NSCLC), is thesubject of four mini-oral presentations and two poster sessions at the16(th) World Conference on Lung Cancer. Hosted by the InternationalAssociation for the Study of Lung Cancer (IASLC), the conference will takeplace September 6-9, 2015 in Denver. "We look forward to sharing updated data from the pivotal TIGER-X trial,analyzing the clinical activity of rociletinib in multiple subsets ofpatients with advanced EGFR mutant NSCLC, specifically in those with ahistory of CNS metastases, as well as in patients with T790M negativedisease," said Patrick J. Mahaffy, President and CEO of Clovis Oncology."The coming months are shaping up to be a very busy and important time forrociletinib, as we move forward with our pivotal TIGER clinical trialprogram and prepare for potential product launches in both the United Statesand Europe."
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.